ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Current perspectives on circulating tumor DNA in breast cancer: a narrative review.
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: In recent years, research and development of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) as cancer biomarkers for use in diagnosis, prognosis, and monitoring of therapeutic responses have progressed. ctDNA has become an important focus for biomarker analysis in breast cancer and in current clinical trials. This review aims to discuss the current status and future prospects of ctDNA in breast cancer. Methods: We provide a Narrative Review about ctDNA in breast cancer. We used PubMed to search for reports of ctDNA in breast cancer. We also searched the clinicaltrials.gov database and the Cochrane Library for clinical trials involving ctDNA analysis in breast cancer and other cancer types up to November 30, 2025 (reviewed November 30, 2025). We reviewed all articles written in English, including clinical trials, meta-analyses, and prospective and retrospective studies. Key Content and Findings: The uses of ctDNA in breast cancer can currently be broadly classified into the following categories: (I) cancer screening; (II) prediction of treatment response in the neoadjuvant setting; (III) monitoring of minimal residual disease; (IV) assessment of the genomic landscape for treatment selection; and (V) monitoring clonal evolution. Clinical trials are underway to assess ctDNA-guided therapy and interventions for ctDNA-positive cases with poor prognosis, especially in the perioperative period. ctDNA is present at low concentrations in the blood in early-stage breast cancer, and a highly sensitive method is needed to detect ctDNA. The U.S. Food and Drug Administration has developed draft guidance regarding the use of ctDNA in therapeutic development. Conclusions: ctDNA has become important as a source of biomarkers in clinical trials, and its clinical and research significance is expected to increase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.